NPM-139

NPM-139 is a miniature, subdermal implant containing semaglutide, developed for chronic weight management in obese and overweight individuals. It utilizes Vivani Medical's proprietary NanoPortal technology to provide smooth and steady delivery of semaglutide, the active ingredient also found in Ozempic and Wegovy. The implant is designed for once or twice-yearly administration, aiming to guarantee medication adherence and potentially improve treatment tolerability compared to injectable formulations. Preclinical studies have demonstrated that a single administration of NPM-139 can result in nearly 20% placebo-adjusted weight loss over a 91-day period in rats, with continuous therapeutic exposure confirmed by pharmacokinetic data. The device is intended to address challenges with real-world adherence seen with current GLP-1 therapies by offering ultra long-acting delivery[1][2][3][6][7].